替罗非班致极重度血小板减少症一例报道  

Extremely Severe Thrombocytopenia Caused by Tirofiban: a Case Report

作　　者：李明珠 徐良成 张勇[1] LI Ming-zhu;XU Liang-cheng;ZHANG Yong(The First People＇ s Hospital of Lianyungang, Lianyungang 222002, Chin)

机构地区：[1]江苏省连云港市第一人民医院,222002

出　　处：《实用心脑肺血管病杂志》2018年第3期119-120,共2页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：替罗非班是一种可逆性糖蛋白Ⅱb/Ⅲa受体拮抗剂,具有抑制血小板聚集、延长出血时间、减少血栓形成等作用,但其具有潜在的致血小板减少及出血风险。本文报道了1例经皮冠状动脉介入术(PCI)后应用替罗非班所致极重度血小板减少症患者,以提高临床医生对替罗非班致极重度血小板减少症的认识。Tirofiban is one of reversible receptor antagonist of glycoprotein GP Ⅱ b/Ⅲ a, can inhibit the aggregation of platelets, lengthen the bleeding time and reduce the thrombosis, but may cause thrombocytopenia and hemorrhage. This paper reported one patient with tirofiban-induced extremely severe thrombocytopenia after PCI, to improve the recognition of clinicians.

关 键 词：血小板减少 替罗非班 病例报告 

分 类 号：R558.2[医药卫生—血液循环系统疾病]